← sources

Tango's chemo-free PRMT5 plus RAS doublet posts 82% response in pretreated MTAP-deleted pancreatic cancer and heads to front-line Phase 3

source: reddit (reddit:StockMarket)published 2026-10-23 14:02ingested 2026-10-24 02:41

retained text

Tango Therapeutics presented Phase 1/2 data at the ESMO congress in Madrid today for vopimetostat, a PRMT5 inhibitor selective for tumours that have lost the MTAP gene, given with Revolution Medicines' RAS inhibitor daraxonrasib. In 22 evaluable previously treated patients with MTAP-deleted RAS-mutant pancreatic cancer, 82% had a tumour response, disease control was 100%, and 88% were progression-free at nine months. No chemotherapy was used. At the 200 mg dose there were no dose-limiting toxicities.

Source:  
[https://www.statnews.com/2026/10/23/esmo-2026-trial-results-tango-therapeutics-vopimetostat-revolution-medicines-rasonque/?utm\_campaign=rss](https://www.statnews.com/2026/10/23/esmo-2026-trial-results-tango-therapeutics-vopimetostat-revolution-medicines-rasonque/?utm_campaign=rss)

What I think this implies:

This is a catalyst for Tango Therapeutics (TNGX). Vopimetostat is their agent and they are taking the exact combination into a global randomised Phase 3 against standard-of-care chemotherapy in front-line MTAP-deleted pancreatic cancer, with dual primary endpoints of response rate and progression-free survival, starting in the first half of 2027.

It also expands the commercial opportunity for Revolution Medicines (RVMD). Daraxonrasib is the other half of the doublet and is currently approved only in previously treated disease, so the front-line trial would reach an untreated population it does not cover today.

Bristol Myers Squibb (BMY) is already running a randomised Phase 2/3 of its own PRMT5 inhibitor with chemotherapy in the same untreated MTAP-deleted pancreatic cancer population, so a competing chemo-free regimen is adverse for that programme. Amgen (AMGN) develops a PRMT5 inhibitor aimed at the same MTAP-deleted tumours and is studying it with daraxonrasib, so the same competitive pressure applies.

The front-line path does not open if the tolerability problems seen at the higher dose appear at 200 mg once a larger, less heavily pretreated population is enrolled, or if Tango cannot secure the daraxonrasib supply needed for the trial.

document fetched 2026-10-24 00:44 · canonical https://reddit.com/r/StockMarket/comments/1xdex80/tangos_chemofree_prmt5_plus_ras_doublet_posts_82